Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. (ACOR): 5 pipeline candidates · ~3 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
3.2 months
N/A
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Acorda Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$10.3M
Quarterly Burn
$20.2M
Runway
3.2 mo
Revenue
$20.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| ampyra | Approved |
| camcevi kit | Approved |
| fampyra | Approved |
| imuldosa | Approved |
| inbrija | Approved |
Frequently asked questions
How many drug candidates are in Acorda Therapeutics, Inc.'s pipeline?
Acorda Therapeutics, Inc. (ACOR) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Acorda Therapeutics, Inc.'s lead drug candidate?
Acorda Therapeutics, Inc.'s most advanced tracked candidate is ampyra (Approved) for improve walking in adults with multiple sclerosis.
What is Acorda Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Acorda Therapeutics, Inc. has approximately 3.2 months of cash runway.
Get the full picture on Acorda Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.